Your Annual Hepatitis C Update


Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States. Baby boomers account for 2 million of the more than 4 million chronic cases, and 75% of the individuals with HCV don’t know they are infected. New treatment options for patients with HCV infection have improved efficacy rates but pose important challenges. In this session, attendees will learn about recommended treatment and management strategies, patient education techniques to improve adherence, and opportunities for pharmacists’ involvement in caring for patients with HCV infection.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Identify important changes in recently updated guidelines that have the potential to influence the management of hepatitis C virus (HCV) infection.
  2. Describe clinically important drug updates, adverse effects, and drug–drug interactions associated with new drug classes used in the treatment of HCV infection.
  3. Outline strategies for improving patient adherence to drug therapy for HCV infection and its comorbidities.


This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP
Associate Professor
University of New Mexico College of Pharmacy
Nimish Patel, Pharm.D., Ph.D., AAHIVP
Associate Professor
University of California, San Diego
Learning Level: Level 2
Track: Pharmacist Clinical Patient Care Services
Session Time Slot(s): 
Saturday, March 23
3:00 PM - 4:30 PM
Washington State Convention Center - Room 613-614
ACPE Pharmacist: 0202-0000-19-045-L01-P
CEUs Pharmacist: .15
Activity Type: